Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry

Jorge E. Cortes, MD, Ricardo Pasquini, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Zhixiang Shen, MD, Carmen Piccolo, MD, Oleg Zernovak, MD, Ramsathish Sivarathinasami, Dawn F. Eng, Dong-Wook Kim, Timothy P. Hughes, MD, MBBS

Blood (2012) 120 (21): 3750.

https://doi.org/10.1182/blood.V120.21.3750.3750

Published: 2012

Journal Articles

A Prognostic Nomogram for Diffuse Large B Cell Lymphoma Incorporating the International Prognostic Index with Interim-PET Findings,

Annie W.S. Chow, MBBS, Teck Siew, MBBS, FRANZCR, Michael Phillips, M.Med.Sci, Mitchell Steve Ward, MB, ChB, FRCP, FRACP, FRCPA, Bradley Augustson, MBBS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, David Joske, MBBS, FRCPA, FRACP

Blood (2011) 118 (21): 3664.

https://doi.org/10.1182/blood.V118.21.3664.3664

Published: 2011

Journal Articles

Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3 rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)

Ricardo Pasquini, MD, Jorge E. Cortes, Hagop M. Kantarjian, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Oleg Zernovak, MD, Ramsathish Sivarathinasami, LaTonya Collins, BSN, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim

Blood (2011) 118 (21): 1695.

https://doi.org/10.1182/blood.V118.21.1695.1695

Published: 2011

Journal Articles

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood (2011) 117 (22): 5827–5834.

https://doi.org/10.1182/blood-2010-10-312603

Published: 2011

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) – 2nd Annual Interim Analysis

Ricardo Pasquini, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Lidia Mongay, MD, PhD, MBA, John Reynolds, PhD, Timothy Hughes, MD, MBBS, Dong-Wook Kim, MD

Blood (2010) 116 (21): 2292.

https://doi.org/10.1182/blood.V116.21.2292.2292

Published: 2010

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L Allen, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, Ian D. Lewis, MD, Miles Prince, MD, MRACMA, FRACP, FRCPA, Sonali Smith, MD, Elaine S Jaffe, MD, Susan Bates, MD

Blood (2009) 114 (22): 1657.

https://doi.org/10.1182/blood.V114.22.1657.1657

Published: 2009

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Ricardo Pasquini, MD, Jorge Cortes-Franco, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Zhixiang Shen, MD, PhD, Luis Meillon, MD, Lidia Mongay, MD, PhD, MBA, Dawn F. Eng, Jim Wang, PhD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD

Blood (2009) 114 (22): 4267.

https://doi.org/10.1182/blood.V114.22.4267.4267

Published: 2009

Journal Articles

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, John P Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Elaine Jaffe, MD, Susan Bates, MD

Blood (2008) 112 (11): 1567.

https://doi.org/10.1182/blood.V112.11.1567.1567

Published: 2008

Journal Articles

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Susan Bates, MD, Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, William Douglas Figg, Sr., PharmD, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRAPC, Mark Kirschbaum, MD, John P. Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Maryalice Stetler- Stevenson, MD, PhD, Alex Ling, MD, Jean Nichols, PhD

Blood (2008) 112 (11): 1568.

https://doi.org/10.1182/blood.V112.11.1568.1568

Published: 2008

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes

Blood (2004) 104 (9): 2926–2932.

https://doi.org/10.1182/blood-2004-03-1134

Published: 2004

Journal Articles

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, Tim Hughes

Blood (2003) 102 (1): 276–283.

https://doi.org/10.1182/blood-2002-09-2896

Published: 2003

NARROW

First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry

A Prognostic Nomogram for Diffuse Large B Cell Lymphoma Incorporating the International Prognostic Index with Interim-PET Findings,

Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3 rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) – 2nd Annual Interim Analysis

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only